Portland, United States
UbiVac, founded in 2005, is a clinical stage biotech company headquartered in the United States. Known for its slogan, An Immunotherapy Company, UbiVac focuses on the research and development of therapeutic immune activators, vaccines, and cellular immunotherapies to combat cancer.
UbiVac's patented technologies leverage a novel class of shared non-mutated cancer neoantigens, identified in 2021, contributing to their treatments' effectiveness. Their lead agent, DPV-001, has undergone an NCI-funded phase I/II adjuvant trial, meeting safety and proof-of-concept criteria. Furthermore, they have partnered with the Providence Cancer Institute and Incyte for a first-in-human trial targeting advanced HNSCC.
The company raised a $250.00K Seed Round investment on April 14, 2022. With a seasoned leadership team bringing over 55 years of expertise, UbiVac is poised to advance its innovative cellular therapy platforms into clinical settings.
